Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients

NCT06683131 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

1160

Enrollment

OTHER

Sponsor class

Conditions

Acute Myocardial Infarction (AMI)

Interventions

DRUG: Tafolecimab

Sponsor

The Affiliated Hospital of Xuzhou Medical University